本文關(guān)鍵詞： 特異質(zhì)型藥物性肝損傷 免疫調(diào)控 化學(xué)藥物 中藥 機(jī)制假說(shuō)　出處：《藥學(xué)學(xué)報(bào)》2017年07期 　論文類型：期刊論文

【摘要】：特異質(zhì)型藥物性肝損傷(idiosyncratic drug-induced liver injury,IDILI)是僅在少數(shù)人群發(fā)生的藥物不良反應(yīng),其發(fā)生往往與服藥時(shí)間、劑量無(wú)明確對(duì)應(yīng)關(guān)系,具有不可預(yù)測(cè)性和發(fā)病率低等特點(diǎn)。研究表明,IDILI是機(jī)體、環(huán)境和藥物因素協(xié)同作用的結(jié)果,而機(jī)體免疫是IDILI發(fā)生的主要誘因。目前,化學(xué)藥物誘導(dǎo)的IDILI研究較為廣泛和深入,形成了多種免疫學(xué)機(jī)制假說(shuō),較好地闡釋了其發(fā)病特點(diǎn)和機(jī)制。近年來(lái),中藥特異質(zhì)肝損傷也逐步被證實(shí),并且形成了中藥特異質(zhì)肝損傷免疫應(yīng)激"三因致毒"機(jī)制假說(shuō),較為全面地揭示了中藥IDILI的發(fā)病特點(diǎn)和機(jī)制。本文就化學(xué)藥物和中藥誘導(dǎo)的IDILI免疫學(xué)機(jī)制假說(shuō)進(jìn)行綜述,以期為IDILI評(píng)價(jià)和臨床風(fēng)險(xiǎn)防控對(duì)策建立提供科學(xué)依據(jù)。
[Abstract]:Idiosyncratic drug-induced liver injury. IDILI is an adverse drug reaction that occurs only in a small number of people. The occurrence of IDILI often has no clear relationship with the time and dosage of taking medicine. It has the characteristics of unpredictability and low incidence. IDILI is the result of the synergistic effect of organism, environment and drug factors, and body immunity is the main inducement of IDILI. At present, the study of chemotherapy-induced IDILI is more extensive and in-depth. Many hypotheses of immunological mechanism have been formed, which have explained its pathogenesis and mechanism. In recent years, the special heterogenous liver injury of traditional Chinese medicine has been gradually proved. And the hypothesis of "three causes of toxic" mechanism of immune stress caused by special heterogenous liver injury of traditional Chinese medicine was formed. The pathogenesis and mechanism of traditional Chinese medicine (IDILI) were comprehensively revealed. The hypothesis of immunological mechanism of IDILI induced by chemical drugs and traditional Chinese medicine was reviewed in this paper. In order to provide scientific basis for the evaluation of IDILI and the establishment of clinical risk prevention and control countermeasures.
【作者單位】： 解放軍302醫(yī)院全軍中醫(yī)藥研究所;北京中醫(yī)藥大學(xué)中藥學(xué)院;解放軍302醫(yī)院中西醫(yī)結(jié)合診療與研究中心;
【基金】：國(guó)家自然科學(xué)基金青年基金資助項(xiàng)目(81503350);國(guó)家自然科學(xué)基金重點(diǎn)資助項(xiàng)目(81630100) 國(guó)家“重大新藥創(chuàng)制”科技重大專項(xiàng)課題(2015ZX09501-004-001-008) 國(guó)家公益性行業(yè)科研專項(xiàng)課題(201507004-04)
【分類號(hào)】：R595.3
【正文快照】： 藥物性肝損傷是指由藥物或其代謝產(chǎn)物導(dǎo)致的的發(fā)生特點(diǎn)和機(jī)制。雖然上述假說(shuō)尚未全面闡釋肝臟損傷,是藥物研發(fā)失敗及撤市的重要原因之一。IDILI的發(fā)生特點(diǎn)和機(jī)制,但免疫在IDILI中的關(guān)鍵藥物性肝損傷可分為固有型和特異質(zhì)型,固有型由作用已被廣泛認(rèn)可,本節(jié)就化學(xué)藥物誘導(dǎo)的IDIL

【參考文獻(xiàn)】

相關(guān)期刊論文 前5條

1 Lanzhi He;Ping Yin;Yakun Meng;Jinfa Tang;Tingting He;Ming Niu;Yuming Guo;Yun Zhu;Jing Jing;Chunyu Li;Zhijie Ma;Jiabo Wang;Zhaofang Bai;Xiaohe Xiao;;Immunological synergistic mechanisms of trans-/cis-stilbene glycosides in Heshouwu-related idiosyncratic liver injury[J];Science Bulletin;2017年11期

2 何婷婷;宮Z，

本文編號(hào)：1484810